SCHEMBL30637476

SCHEMBL30637476

O=C(/C=C/c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)c(O)c3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 5/20 0.93
▸ CA12 O43570 5/20 0.91
▸ CA4 P22748 5/20 0.91
▸ CA7 P43166 5/20 0.91
▸ CYP3A4 P08684 3/20 0.91
▸ TYR P14679 1/20 0.91
▸ CA2 P00918 4/20 0.79
▸ KDM4E B2RXH2 7/20 0.69
▸ GAA P10253 5/20 0.69
▸ MAPT P10636 5/20 0.69
▸ POLB P06746 4/20 0.69
▸ P4HB P07237 4/20 0.69
▸ EPHX2 P34913 3/20 0.69
▸ ADRA2C P18825 2/20 0.69
▸ KDM1A O60341 2/20 0.69
▸ HMGB1 P09429 2/20 0.69
▸ MAOA P21397 2/20 0.69
▸ XDH P47989 2/20 0.69
▸ MAPK1 P28482 2/20 0.69
▸ ALPI P09923 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12377097 1.00 AKR1B1 (0.93) AKR1B1CA12CA4CA7CYP3A4
SCHEMBL13963384 0.95 AKR1B1 (0.93) AKR1B1CA12CA4CA7CYP3A4
SCHEMBL16131012 0.95 AKR1B1 (0.93) AKR1B1CA12CA4CA7CYP3A4
SCHEMBL13973823 0.95 AKR1B1 (0.93) AKR1B1CA12CA4CA7CYP3A4
Tiliroside SCHEMBL16131015 0.95 CA12 (1.00) AKR1B1CA12CA4CA7CYP3A4
Tiliroside SCHEMBL13963382 0.95 CA12 (1.00) AKR1B1CA12CA4CA7CYP3A4
Tiliroside SCHEMBL12568460 0.95 CA12 (1.00) AKR1B1CA12CA4CA7CYP3A4
Tiliroside SCHEMBL23598 0.95 CA12 (1.00) AKR1B1CA12CA4CA7CYP3A4
Tiliroside SCHEMBL12568488 0.95 CA12 (1.00) AKR1B1CA12CA4CA7CYP3A4
Tiliroside SCHEMBL15756208 0.95 CA12 (1.00) AKR1B1CA12CA4CA7CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 — — WO claimed
EP-4622640-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF Brightseed, Inc. (US) 2025-10-01 — — EP disclosed
US-20250281451-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF BRIGHTSEED, INC. 2025-09-11 — — US disclosed
WO-2024112947-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF BRIGHTSEED, INC. (US) 2024-05-30 — — WO disclosed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281451-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF PER2, PYGB, CRY2 AKR1B1 4602/4885CA12 4544/4885CA4 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback